Your browser doesn't support javascript.
loading
BCL2 genotypes and prostate cancer survival.
Renner, Wilfried; Langsenlehner, Uwe; Krenn-Pilko, Sabine; Eder, Petra; Langsenlehner, Tanja.
Afiliación
  • Renner W; Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036, Graz, Austria. wilfried.renner@medunigraz.at.
  • Langsenlehner U; Division of Internal Medicine, GKK Outpatient Department, Graz, Austria.
  • Krenn-Pilko S; Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria.
  • Eder P; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
  • Langsenlehner T; Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria.
Strahlenther Onkol ; 193(6): 466-471, 2017 Jun.
Article en En | MEDLINE | ID: mdl-28396899
PURPOSE: The antiapoptotic B­cell lymphoma 2 (BCL2) gene is a key player in cancer development and progression. A functional single-nucleotide polymorphism (c.-938C>A, rs2279115) in the inhibitory P2 BCL2 gene promoter has been associated with clinical outcomes in various types of cancer. Aim of the present study was to analyze the role of BCL2-938C>A genotypes in prostate cancer mortality. METHODS: The association between BCL2-938C>A (rs2279115) genotypes and prostate cancer outcome was studied within the prospective PROCAGENE study comprising 702 prostate cancer patients. RESULTS: During a median follow-up time of 92 months, 120 (17.1%) patients died. A univariate Cox regression model showed a significant association of the CC genotype with reduced cancer-specific survival (CSS; hazard ratio, HR, 2.13, 95% confidence interval, CI, 1.10-4.12; p = 0.024) and overall survival (OS; HR 2.34, 95% CI 1.58-3.47; p < 0.001). In a multivariate Cox regression model including age at diagnosis, risk group, and androgen deprivation therapy, the CC genotype remained a significant predictor of poor CSS (HR 2.05, 95% CI 1.05-3.99; p = 0.034) and OS (HR 2.25, 95% CI 1.51-3.36; p < 0.001). CONCLUSION: This study provides evidence that the homozygous BCL2-938 CC genotype is associated with OS and C in prostate cancer patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteínas Proto-Oncogénicas c-bcl-2 / Genotipo Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Strahlenther Onkol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2017 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteínas Proto-Oncogénicas c-bcl-2 / Genotipo Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Strahlenther Onkol Asunto de la revista: NEOPLASIAS / RADIOTERAPIA Año: 2017 Tipo del documento: Article País de afiliación: Austria Pais de publicación: Alemania